Obesity in 2010: the future of obesity medicine: where do we go from here?
about
Contribution of common non-synonymous variants in PCSK1 to body mass index variation and risk of obesity: a systematic review and meta-analysis with evidence from up to 331 175 individualsDesign, Synthesis, Structural and Functional Characterization of Novel Melanocortin Agonists Based on the Cyclotide Kalata B1Myths, presumptions, and facts about obesity.Evaluation of AMG 076, a potent and selective MCHR1 antagonist, in rodent and primate obesity modelsPotential use of exenatide for the treatment of obesity.Intestinal removal of free fatty acids from hosts by Lactobacilli for the treatment of obesity.
P2860
Obesity in 2010: the future of obesity medicine: where do we go from here?
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on February 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Obesity in 2010: the future of obesity medicine: where do we go from here?
@en
Obesity in 2010: the future of obesity medicine: where do we go from here?
@nl
type
label
Obesity in 2010: the future of obesity medicine: where do we go from here?
@en
Obesity in 2010: the future of obesity medicine: where do we go from here?
@nl
prefLabel
Obesity in 2010: the future of obesity medicine: where do we go from here?
@en
Obesity in 2010: the future of obesity medicine: where do we go from here?
@nl
P2860
P356
P1476
Obesity in 2010: the future of obesity medicine: where do we go from here?
@en
P2093
Louis J Aronne
Suzanne M Wright
P2860
P2888
P356
10.1038/NRENDO.2010.231
P577
2011-02-01T00:00:00Z